Yun Lin Li

US Patent:

20080167288, Jul 10, 2008

Filed:

Feb 15, 2008

Appl. No.:

12/070310

Inventors:

Yun Long Li - Wilmington DE, US
Jincong Zhuo - Marcus Hook PA, US
David Burns - Philadelphia PA, US
Wanqing Yao - Kennett Square PA, US
Ravi Kumar Jalluri - Avondale PA, US

Assignee:

Lncyte Corporation - Wilmington DE

International Classification:

A61K 31/397
C07D 221/00
A61K 31/4523
C07D 295/00
A61K 31/5377
A61P 17/00
A61P 37/00
A61P 29/00
A61K 31/496
C07D 209/02
A61K 31/403
C07D 213/02
A61K 31/44
C07D 221/02
A61K 31/435
C07D 241/36
A61K 31/498
C07D 207/00
A61K 31/541
A61P 9/00
A61K 31/40
C07D 215/00
A61K 31/47
A61P 35/00
A61P 19/02
C07D 205/02

US Classification:

51421018, 546194, 514318, 544129, 5142355, 546187, 514316, 544360, 51425301, 546208, 514326, 548469, 514415, 546314, 514354, 546112, 514299, 544349, 514249, 548530, 514423, 546152, 514314, 544121, 5142358, 548953, 544 60, 5142278

Abstract:

The present invention provides compounds of the formula:its enantiomers, diastereomers, racemic mixtures thereof, prodrugs, crystalline forms, non-crystalline forms, amorphous forms thereof, solvates thereof, metabolites thereof, and pharmaceutically acceptable salts, wherein the ring A substituent groups are fully defined in the following disclosure. The compounds of formula are inhibitors of metalloproteases such as matrix metalloproteases and sheddases, and are useful in treating diseases such as rheumatoid arthritis, psoriasis, neoplastic diseases, allergies and all those diseases wherein inhibition of MMPs is desirable.

US Patent:

20130004983, Jan 3, 2013

Filed:

Dec 6, 2010

Appl. No.:

13/513600

Inventors:

Hiroaki Matsunami - Durham NC, US
Yun Li - Philadelphia PA, US

International Classification:

C12N 5/071
C12Q 1/02

US Classification:

435 29, 435369

Abstract:

The present invention relates to polypeptides capable of modulating odorant receptor activation. In particular, the present invention provides polypeptides (e.g., type 3 muscarinic actetylcholine receptor M3) capable of enhancing odorant receptor activation. The present invention further provides assays for the detection of ligands specific for various odorant receptors. Additionally, the present invention provides methods of screening for polypeptide polymorphisms and mutations associated with odorant receptor activation (e.g., polymorphisms and mutations associated with muscarinic actetylcholine receptor polypeptides (e.g., M1, M2 M3, M4, M5)), as well as methods of screening for therapeutic agents, ligands, and modulators of such proteins.

US Patent:

20210139986, May 13, 2021

Filed:

Dec 31, 2020

Appl. No.:

17/139266

Inventors:

- Durham NC, US
Yun Li - Philadelphia PA, US

International Classification:

C12Q 1/6881
C07K 14/705

Abstract:

The present invention relates to polypeptides capable of modulating odorant receptor activation. In particular, the present invention provides polypeptides (e.g., type 3 muscarinic actetylcholine receptor M3) capable of enhancing odorant receptor activation. The present invention further provides assays for the detection of ligands specific for various odorant receptors. Additionally, the present invention provides methods of screening for polypeptide polymorphisms and mutations associated with odorant receptor activation (e.g., polymorphisms and mutations associated with muscarinic actetylcholine receptor polypeptides (e.g., M1, M2, M3, M4, M5)), as well as methods of screening for therapeutic agents, ligands, and modulators of such proteins.

US Patent:

20200080152, Mar 12, 2020

Filed:

Aug 20, 2019

Appl. No.:

16/545469

Inventors:

- Philadelphia PA, US
Yun Rose Li - Philadelphia PA, US
Brendan Keating - Philadelphia PA, US

International Classification:

C12Q 1/6883

Abstract:

This disclosure provides new genetic targets, diagnostic methods, and therapeutic treatment regimens for multiple autoimmune disorders, including pediatric autoimmune disorders that are co-inherited and genetically shared. The disclosure, for example, provides methods of diagnosing or determining a susceptibility for one or more autoimmune diseases and methods of determining treatment protocols for patients with one or more autoimmune diseases based on determining if the patients have genetic alterations in particular genes.

US Patent:

20190002980, Jan 3, 2019

Filed:

Sep 10, 2018

Appl. No.:

16/126581

Inventors:

- Durham NC, US
Yun Li - Philadelphia PA, US

International Classification:

C12Q 1/6881
C07K 14/705

Abstract:

The present invention relates to polypeptides capable of modulating odorant receptor activation. In particular, the present invention provides polypeptides (e.g., type 3 muscarinic actetylcholine receptor M3) capable of enhancing odorant receptor activation. The present invention further provides assays for the detection of ligands specific for various odorant receptors. Additionally, the present invention provides methods of screening for polypeptide polymorphisms and mutations associated with odorant receptor activation (e.g., polymorphisms and mutations associated with muscarinic actetylcholine receptor polypeptides (e.g., M1, M2, M3, M4, M5)), as well as methods of screening for therapeutic agents, ligands, and modulators of such proteins.

US Patent:

20170283872, Oct 5, 2017

Filed:

Apr 3, 2017

Appl. No.:

15/477873

Inventors:

- Durham NC, US
Yun Li - Philadelphia PA, US

International Classification:

C12Q 1/68
C07K 14/705

Abstract:

The present invention relates to polypeptides capable of modulating odorant receptor activation. In particular, the present invention provides polypeptides (e.g., type 3 muscarinic actetylcholine receptor M3) capable of enhancing odorant receptor activation. The present invention further provides assays for the detection of ligands specific for various odorant receptors. Additionally, the present invention provides methods of screening for polypeptide polymorphisms and mutations associated with odorant receptor activation (e.g., polymorphisms and mutations associated with muscarinic actetylcholine receptor polypeptides (e.g., M1, M2, M3, M4, M5)), as well as methods of screening for therapeutic agents, ligands, and modulators of such proteins.

US Patent:

20170051351, Feb 23, 2017

Filed:

Aug 19, 2016

Appl. No.:

15/242091

Inventors:

- Philadelphia PA, US
Yun Rose Li - Philadelphia PA, US
Brendan Keating - Philadelphia PA, US

International Classification:

C12Q 1/68

Abstract:

This disclosure provides new genetic targets, diagnostic methods, and therapeutic treatment regimens for multiple autoimmune disorders, including pediatric autoimmune disorders that are co-inherited and genetically shared. The disclosure, for example, provides methods of diagnosing or determining a susceptibility for one or more autoimmune diseases and methods of determining treatment protocols for patients with one or more autoimmune diseases based on determining if the patients have genetic alterations in particular genes.

US Patent:

20170051352, Feb 23, 2017

Filed:

Aug 19, 2016

Appl. No.:

15/242210

Inventors:

- Philadelphia PA, US
Charlly Kao - Philadelphia PA, US
Christopher Cardinale - Philadelphia PA, US
Rahul Pandey - Philadelphia PA, US
Yun Rose Li - Philadelphia PA, US

International Classification:

C12Q 1/68
C07K 16/24
C12N 15/113

Abstract:

The present disclosure relates to methods of treating autoimmune conditions in patients who have genetic alterations in the TNFRSF6B gene, which codes for the decoy receptor 3 protein (DcR3), for example that reduce the expression, secretion, or ligand binding activity of DcR3. For example, in some embodiments, the conditions may be treated with molecules that inhibit the activity of DcR3 ligands such as LIGHT, TL1A, and FasL, such as anti-LIGHT, anti-TL1A, and anti-FasL antibodies, or inhibitors of the non-canonical NF-κB pathway.